Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2014

Open Access 01-12-2014 | Review

The therapeutic target of estrogen receptor-alpha36 in estrogen-dependent tumors

Authors: Yu Gu, Tianxiang Chen, Elena López, Weizhu Wu, Xiangdong Wang, Jiang Cao, Lisong Teng

Published in: Journal of Translational Medicine | Issue 1/2014

Login to get access

Abstract

Estrogen receptor-alpha36 (ER-α36) is a new isoform of estrogen receptors without transcriptional activation domains of the classical ER-α(ER − α66). ER-α36 is mainly located in cytoplasm and plasma membrane. ER-α36 mediates non-genomic signaling and is involved in genomic signaling of other ERs. Recently ER-α36 is found to play a critical role in the development of estrogen-dependent cancers and endocrine resistance of breast cancer. The present article overviews and updates the biological nature and function of ER-α36, potential interaction of ER-α36 with other estrogen receptors and growth factor receptors, intracellular signaling pathways, potential mechanism by which ER-α36 may play an important role in the development of tumor resistance to endocrine therapies.
Appendix
Available only for authorised users
Literature
1.
Shao W, Brown M: Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapy. Breast Cancer Res. 2004, 6: 39-52. 10.1186/bcr742.PubMedCentralCrossRefPubMed
2.
Jensen EV, Jacobson HI: Basic guides to the mechanism of estrogen action. Recent Prog Horm Res. 1962, 18: 387-
3.
Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA: Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci U S A. 1996, 93: 5925-5930. 10.1073/pnas.93.12.5925.PubMedCentralCrossRefPubMed
4.
Murphy LC, Dotzlaw H, Leygue E, Douglas D, Coutts A, Watson PH: Estrogen receptor variants and mutations. J Steroid Biochem Mol Biol. 1997, 62: 363-372. 10.1016/S0960-0760(97)00084-8.CrossRefPubMed
5.
Zhang QX, Hilsenbeck SG, Fuqua SA, Borg A: Multiple splicing variants of the estrogen receptor are present in individual human breast tumors. J Steroid Biochem Mol Biol. 1996, 59: 251-260. 10.1016/S0960-0760(96)00120-3.CrossRefPubMed
6.
Wang Z, Zhang X, Shen P, Loggie BW, Chang Y, Deuel TF: Identification, cloning, and expression of human estrogen receptor-alpha36, a novel variant of human estrogen receptor-alpha66. Biochem Biophys Res Commun. 2005, 336: 1023-1027. 10.1016/j.bbrc.2005.08.226.CrossRefPubMed
7.
Wang Z, Zhang X, Shen P, Loggie BW, Chang Y, Deuel TF: A variant of estrogen receptor-{alpha}, hER-{alpha}36: transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling. Proc Natl Acad Sci U S A. 2006, 103: 9063-9068. 10.1073/pnas.0603339103.PubMedCentralCrossRefPubMed
8.
Pearce ST, Jordan VC: The biological role of estrogen receptors alpha and beta in cancer. Crit Rev Oncol Hematol. 2004, 50: 3-22. 10.1016/j.critrevonc.2003.09.003.CrossRefPubMed
9.
van der Eerden BC, Emons J, Ahmed S, Van Essen HW, Lowik CW, Wit JM, Karperien M: Evidence for genomic and nongenomic actions of estrogen in growth plate regulation in female and male rats at the onset of sexual maturation. J Endocrinol. 2002, 175: 277-288. 10.1677/joe.0.1750277.CrossRefPubMed
10.
Bjornstrom L, Sjoberg M: Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Mol Endocrinol. 2005, 19: 833-842. 10.1210/me.2004-0486.CrossRefPubMed
11.
Cheskis BJ, Greger JG, Nagpal S, Freedman LP: Signaling by estrogens. J Cell Physiol. 2007, 213: 610-617. 10.1002/jcp.21253.CrossRefPubMed
12.
Osborne CK, Schiff R: Estrogen-receptor biology: continuing progress and therapeutic implications. J Clin Oncol. 2005, 23: 1616-1622. 10.1200/JCO.2005.10.036.CrossRefPubMed
13.
Weihua Z, Andersson S, Cheng G, Simpson ER, Warner M, Gustafsson JA: Update on estrogen signaling. FEBS Lett. 2003, 546: 17-24. 10.1016/S0014-5793(03)00436-8.CrossRefPubMed
14.
Kong EH, Pike AC, Hubbard RE: Structure and mechanism of the oestrogen receptor. Biochem Soc Trans. 2003, 31: 56-59.CrossRefPubMed
15.
Hall JM, McDonnell DP: The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology. 1999, 140: 5566-5578.PubMed
16.
Lee LM, Cao J, Deng H, Chen P, Gatalica Z, Wang ZY: ER-alpha36, a novel variant of ER-alpha, is expressed in ER-positive and -negative human breast carcinomas. Anticancer Res. 2008, 28: 479-483.PubMedCentralPubMed
17.
Tu BB, Lin SL, Yan LY, Wang ZY, Sun QY, Qiao J: ER-alpha36, a novel variant of estrogen receptor alpha, is involved in EGFR-related carcinogenesis in endometrial cancer. Am J Obstet Gynecol. 2011, 205 (227): e221-e226.
18.
Jiang H, Teng R, Wang Q, Zhang X, Wang H, Wang Z, Cao J, Teng L: Transcriptional analysis of estrogen receptor alpha variant mRNAs in colorectal cancers and their matched normal colorectal tissues. J Steroid Biochem Mol Biol. 2008, 112: 20-24. 10.1016/j.jsbmb.2008.07.004.CrossRefPubMed
19.
Wang J, Li J, Fang R, Xie S, Wang L, Xu C: Expression of ERalpha36 in gastric cancer samples and their matched normal tissues. Oncol Lett. 2012, 3: 172-175.PubMedCentralPubMed
20.
Miceli V, Cocciadiferro L, Fregapane M, Zarcone M, Montalto G, Polito LM, Agostara B, Granata OM, Carruba G: Expression of wild-type and variant estrogen receptor alpha in liver carcinogenesis and tumor progression. OMICS. 2011, 15: 313-317. 10.1089/omi.2010.0108.CrossRefPubMed
21.
Chakraborty P, Roy SK: Expression of estrogen receptor alpha 36 (ESR36) in the hamster ovary throughout the estrous cycle: effects of gonadotropins. PLoS One. 2013, 8: e58291-10.1371/journal.pone.0058291.PubMedCentralCrossRefPubMed
22.
Acconcia F, Ascenzi P, Bocedi A, Spisni E, Tomasi V, Trentalance A, Visca P, Marino M: Palmitoylation-dependent estrogen receptor alpha membrane localization: regulation by 17beta-estradiol. Mol Biol Cell. 2005, 16: 231-237.PubMedCentralCrossRefPubMed
23.
Baulieu EE, Binart N, Cadepond F, Catelli MG, Chambraud B, Garnier J, Gasc JM, Groyer-Schweizer G, Oblin ME, Radanyi C: Receptor-associated nuclear proteins and steroid/antisteroid action. Ann N Y Acad Sci. 1990, 595: 300-315. 10.1111/j.1749-6632.1990.tb34304.x.CrossRefPubMed
24.
Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H: Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science. 1995, 270: 1491-1494. 10.1126/science.270.5241.1491.CrossRefPubMed
25.
Aronica SM, Kraus WL, Katzenellenbogen BS: Estrogen action via the cAMP signaling pathway: stimulation of adenylate cyclase and cAMP-regulated gene transcription. Proc Natl Acad Sci U S A. 1994, 91: 8517-8521. 10.1073/pnas.91.18.8517.PubMedCentralCrossRefPubMed
26.
Zou Y, Ding L, Coleman M, Wang Z: Estrogen receptor-alpha (ER-alpha) suppresses expression of its variant ER-alpha 36. FEBS Lett. 2009, 583: 1368-1374. 10.1016/j.febslet.2009.03.047.PubMedCentralCrossRefPubMed
27.
Kang L, Wang L, Wang ZY: Opposite regulation of estrogen receptor-alpha and its variant ER-alpha36 by the Wilms’ tumor suppressor WT1. Oncol Lett. 2011, 2: 337-341.PubMedCentralPubMed
28.
Carmeci C, Thompson DA, Ring HZ, Francke U, Weigel RJ: Identification of a gene (GPR30) with homology to the G-protein-coupled receptor superfamily associated with estrogen receptor expression in breast cancer. Genomics. 1997, 45: 607-617. 10.1006/geno.1997.4972.CrossRefPubMed
29.
Filardo E, Quinn J, Pang Y, Graeber C, Shaw S, Dong J, Thomas P: Activation of the novel estrogen receptor G protein-coupled receptor 30 (GPR30) at the plasma membrane. Endocrinology. 2007, 148: 3236-3245. 10.1210/en.2006-1605.CrossRefPubMed
30.
Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER: A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science. 2005, 307: 1625-1630. 10.1126/science.1106943.CrossRefPubMed
31.
Kang L, Zhang X, Xie Y, Tu Y, Wang D, Liu Z, Wang ZY: Involvement of estrogen receptor variant ER-alpha36, not GPR30, in nongenomic estrogen signaling. Mol Endocrinol. 2010, 24: 709-721. 10.1210/me.2009-0317.PubMedCentralCrossRefPubMed
32.
Wallacides A, Chesnel A, Ajj H, Chillet M, Flament S, Dumond H: Estrogens promote proliferation of the seminoma-like TCam-2 cell line through a GPER-dependent ERalpha36 induction. Mol Cell Endocrinol. 2012, 350: 61-71. 10.1016/j.mce.2011.11.021.CrossRefPubMed
33.
Vranic S, Gatalica Z, Deng H, Frkovic-Grazio S, Lee LM, Gurjeva O, Wang ZY: ER-alpha36, a novel isoform of ER-alpha66, is commonly over-expressed in apocrine and adenoid cystic carcinomas of the breast. J Clin Pathol. 2011, 64: 54-57. 10.1136/jcp.2010.082776.PubMedCentralCrossRefPubMed
34.
Zhang XT, Kang LG, Ding L, Vranic S, Gatalica Z, Wang ZY: A positive feedback loop of ER-alpha36/EGFR promotes malignant growth of ER-negative breast cancer cells. Oncogene. 2011, 30: 770-780. 10.1038/onc.2010.458.PubMedCentralCrossRefPubMed
35.
Zhang XT, Ding L, Kang LG, Wang ZY: Involvement of ER-alpha36, Src, EGFR and STAT5 in the biphasic estrogen signaling of ER-negative breast cancer cells. Oncol Rep. 2012, 27: 2057-2065.PubMedCentralPubMed
36.
Lin SL, Yan LY, Zhang XT, Yuan J, Li M, Qiao J, Wang ZY, Sun QY: ER-alpha36, a variant of ER-alpha, promotes tamoxifen agonist action in endometrial cancer cells via the MAPK/ERK and PI3K/Akt pathways. PLoS One. 2010, 5: e9013-10.1371/journal.pone.0009013.PubMedCentralCrossRefPubMed
37.
Li G, Zhang J, Jin K, He K, Zheng Y, Xu X, Wang H, Wang H, Li Z, Yu X: Estrogen receptor-α36 is involved in development of acquired tamoxifen resistance via regulating the growth status switch in breast cancer cells. Mol Oncol. 2013, 7: 611-624. 10.1016/j.molonc.2013.02.001.CrossRefPubMed
38.
Shi L, Dong B, Li Z, Lu Y, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B: Expression of ER-{alpha}36, a novel variant of estrogen receptor {alpha}, and resistance to tamoxifen treatment in breast cancer. J Clin Oncol. 2009, 27: 3423-3429. 10.1200/JCO.2008.17.2254.PubMedCentralCrossRefPubMed
39.
Kang L, Guo Y, Zhang X, Meng J, Wang ZY: A positive cross-regulation of HER2 and ER-alpha36 controls ALDH1 positive breast cancer cells. J Steroid Biochem Mol Biol. 2011, 127: 262-268. 10.1016/j.jsbmb.2011.08.011.PubMedCentralCrossRefPubMed
40.
Dufourny B, Alblas J, Van Teeffelen HA, Van Schaik FM, van der Burg B, Steenbergh PH, Sussenbach JS: Mitogenic signaling of insulin-like growth factor I in MCF-7 human breast cancer cells requires phosphatidylinositol 3-kinase and is independent of mitogen-activated protein kinase. J Biol Chem. 1997, 272: 31163-31171. 10.1074/jbc.272.49.31163.CrossRefPubMed
41.
Lin SL, Yan LY, Liang XW, Wang ZB, Wang ZY, Qiao J, Schatten H, Sun QY: A novel variant of ER-alpha, ER-alpha36 mediates testosterone-stimulated ERK and Akt activation in endometrial cancer Hec1A cells. Reprod Biol Endocrinol. 2009, 7: 102-10.1186/1477-7827-7-102.PubMedCentralCrossRefPubMed
42.
Ohshiro K, Schwartz AM, Levine PH, Kumar R: Alternate estrogen receptors promote invasion of inflammatory breast cancer cells via non-genomic signaling. PLoS One. 2012, 7: e30725-10.1371/journal.pone.0030725.PubMedCentralCrossRefPubMed
43.
McMillan J, Fatehi-Sedeh S, Sylvia VL, Bingham V, Zhong M, Boyan BD, Schwartz Z: Sex-specific regulation of growth plate chondrocytes by estrogen is via multiple MAP kinase signaling pathways. Biochim Biophys Acta. 2006, 1763: 381-392. 10.1016/j.bbamcr.2006.02.010.CrossRefPubMed
44.
Tong JS, Zhang QH, Wang ZB, Li S, Yang CR, Fu XQ, Hou Y, Wang ZY, Sheng J, Sun QY: ER-alpha36, a novel variant of ER-alpha, mediates estrogen-stimulated proliferation of endometrial carcinoma cells via the PKCdelta/ERK pathway. PLoS One. 2010, 5: e15408-10.1371/journal.pone.0015408.PubMedCentralCrossRefPubMed
45.
Chaudhri RA, Olivares-Navarrete R, Cuenca N, Hadadi A, Boyan BD, Schwartz Z: Membrane estrogen signaling enhances tumorigenesis and metastatic potential of breast cancer cells via estrogen receptor-alpha36 (ERalpha36). J Biol Chem. 2012, 287: 7169-7181. 10.1074/jbc.M111.292946.PubMedCentralCrossRefPubMed
46.
Wagner EF, Nebreda AR: Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer. 2009, 9: 537-549. 10.1038/nrc2694.CrossRefPubMed
47.
Zhang J, Li G, Li Z, Yu X, Zheng Y, Jin K, Wang H, Gong Y, Sun X, Teng X: Estrogen-independent effects of ER-alpha36 in ER-negative breast cancer. Steroids. 2012, 77: 666-673. 10.1016/j.steroids.2012.02.013.CrossRefPubMed
48.
Horwitz SB: Taxol (paclitaxel): mechanisms of action. Ann Oncol. 1994, 5 (Suppl 6): S3-S6.PubMed
49.
Jordan NJ, Gee JM, Barrow D, Wakeling AE, Nicholson RI: Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cells. Breast Cancer Res Treat. 2004, 87: 167-180. 10.1023/B:BREA.0000041623.21338.47.CrossRefPubMed
50.
Graf GA, Matveev SV, Smart EJ: Class B scavenger receptors, caveolae and cholesterol homeostasis. Trends Cardiovasc Med. 1999, 9: 221-225. 10.1016/S1050-1738(00)00031-1.CrossRefPubMed
51.
Lee SW, Reimer CL, Oh P, Campbell DB, Schnitzer JE: Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells. Oncogene. 1998, 16: 1391-1397. 10.1038/sj.onc.1201661.CrossRefPubMed
52.
Sloan EK, Stanley KL, Anderson RL: Caveolin-1 inhibits breast cancer growth and metastasis. Oncogene. 2004, 23: 7893-7897. 10.1038/sj.onc.1208062.CrossRefPubMed
53.
Wang D, Huang P, Zhu B, Sun L, Huang Q, Wang J: Induction of estrogen receptor α-36 expression by bone morphogenetic protein 2 in breast cancer cell lines. Mol Med Rep. 2012, 6: 591-596.PubMed
54.
Poola I, Koduri S, Chatra S, Clarke R: Identification of twenty alternatively spliced estrogen receptor alpha mRNAs in breast cancer cell lines and tumors using splice targeted primer approach. J Steroid Biochem Mol Biol. 2000, 72: 249-258. 10.1016/S0960-0760(00)00033-9.CrossRefPubMed
55.
Gotteland M, Desauty G, Delarue JC, Liu L, May E: Human estrogen receptor messenger RNA variants in both normal and tumor breast tissues. Mol Cell Endocrinol. 1995, 112: 1-13. 10.1016/0303-7207(95)03576-S.CrossRefPubMed
56.
Pfeffer U, Fecarotta E, Vidali G: Coexpression of multiple estrogen receptor variant messenger RNAs in normal and neoplastic breast tissues and in MCF-7 cells. Cancer Res. 1995, 55: 2158-2165.PubMed
57.
Leygue E, Huang A, Murphy LC, Watson PH: Prevalence of estrogen receptor variant messenger RNAs in human breast cancer. Cancer Res. 1996, 56: 4324-4327.PubMed
58.
Pelekanou V, Notas G, Kampa M, Tsentelierou E, Radojicic J, Leclercq G, Castanas E, Stathopoulos EN: ERα36, a new variant of the ERα is expressed in triple negative breast carcinomas and has a specific transcriptomic signature in breast cancer cell lines. Steroids. 2012, 77: 928-934. 10.1016/j.steroids.2011.12.016.CrossRefPubMed
59.
Zheng Y, Zhang J, Xu ZZ, Sheng JM, Zhang XC, Wang HH, Teng XD, Liu XJ, Cao J, Teng LS: Quantitative profiles of the mRNAs of ER-alpha and its novel variant ER-alpha36 in breast cancers and matched normal tissues. J Zhejiang Univ Sci B. 2010, 11: 144-150. 10.1631/jzus.B0900266.PubMedCentralCrossRefPubMed
60.
Sun L, Wang J, Zhang L, Li X, Shen D: Expression of ER-α36, a novel variant of estrogen receptor in endometrial carcinoma and its clinical significance. Gynecol Obstet Invest. 2013, 75: 68-72. 10.1159/000339933.CrossRefPubMed
61.
Deng H, Huang X, Fan J, Wang L, Xia Q, Yang X, Wang Z, Liu L: A variant of estrogen receptor-alpha, ER-alpha36 is expressed in human gastric cancer and is highly correlated with lymph node metastasis. Oncol Rep. 2010, 24: 171-6.PubMedCentralPubMed
62.
Zhang CC, Shapiro DJ: Activation of the p38 mitogen-activated protein kinase pathway by estrogen or by 4-hydroxytamoxifen is coupled to estrogen receptor-induced apoptosis. J Biol Chem. 2000, 275: 479-486. 10.1074/jbc.275.1.479.CrossRefPubMed
63.
Gu Q, Korach KS, Moss RL: Rapid action of 17beta-estradiol on kainate-induced currents in hippocampal neurons lacking intracellular estrogen receptors. Endocrinology. 1999, 140: 660-666.PubMed
64.
Dutertre M, Smith CL: Molecular mechanisms of selective estrogen receptor modulator (SERM) action. J Pharmacol Exp Ther. 2000, 295: 431-437.PubMed
65.
Zhao Y, Deng C, Lu W, Xiao J, Ma D, Guo M, Recker RR, Gatalica Z, Wang Z, Xiao GG: let-7 microRNAs induce tamoxifen sensitivity by downregulation of estrogen receptor alpha signaling in breast cancer. Mol Med. 2011, 17: 1233-1241.PubMedCentralCrossRefPubMed
66.
Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989, 244: 707-712. 10.1126/science.2470152.CrossRefPubMed
67.
Dowsett M: Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer. Endocr Relat Cancer. 2001, 8: 191-195. 10.1677/erc.0.0080191.CrossRefPubMed
68.
Fawell SE, White R, Hoare S, Sydenham M, Page M, Parker MG: Inhibition of estrogen receptor-DNA binding by the “pure” antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization. Proc Natl Acad Sci U S A. 1990, 87: 6883-6887. 10.1073/pnas.87.17.6883.PubMedCentralCrossRefPubMed
69.
Dauvois S, Danielian PS, White R, Parker MG: Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc Natl Acad Sci U S A. 1992, 89: 4037-4041. 10.1073/pnas.89.9.4037.PubMedCentralCrossRefPubMed
70.
Nicholson RI, Gee JM, Manning DL, Wakeling AE, Montano MM, Katzenellenbogen BS: Responses to pure antiestrogens (ICI 164384, ICI 182780) in estrogen-sensitive and -resistant experimental and clinical breast cancer. Ann N Y Acad Sci. 1995, 761: 148-163. 10.1111/j.1749-6632.1995.tb31376.x.CrossRefPubMed
71.
Kang L, Wang ZY: Breast cancer cell growth inhibition by phenethyl isothiocyanate is associated with down-regulation of oestrogen receptor-alpha36. J Cell Mol Med. 2010, 14: 1485-1493.PubMedCentralCrossRefPubMed
72.
Mahfoudi A, Roulet E, Dauvois S, Parker MG, Wahli W: Specific mutations in the estrogen receptor change the properties of antiestrogens to full agonists. Proc Natl Acad Sci U S A. 1995, 92: 4206-4210. 10.1073/pnas.92.10.4206.PubMedCentralCrossRefPubMed
73.
Pearce ST, Liu H, Jordan VC: Modulation of estrogen receptor alpha function and stability by tamoxifen and a critical amino acid (Asp-538) in helix 12. J Biol Chem. 2003, 278: 7630-7638. 10.1074/jbc.M211129200.CrossRefPubMed
74.
Geisler J, Haynes B, Anker G, Dowsett M, Lonning PE: Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol. 2002, 20: 751-757. 10.1200/JCO.20.3.751.CrossRefPubMed
75.
Zambetti M, Mansutti M, Gomez P, Lluch A, Dittrich C, Zamagni C, Ciruelos E, Pavesi L, Semiglazov V, De Benedictis E: Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II). Breast Cancer Res Treat. 2012, 132: 843-851. 10.1007/s10549-011-1660-6.CrossRefPubMed
76.
Sui M, Huang Y, Park BH, Davidson NE, Fan W: Estrogen receptor alpha mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death. Cancer Res. 2007, 67: 5337-5344. 10.1158/0008-5472.CAN-06-4582.CrossRefPubMed
77.
Sun L, Wang J, Zhang L, Li X, Shen D: Expression of ER-α36, a novel variant of estrogen receptor in endometrial carcinoma and its clinical significance. Gynecol Obstet Invest. 2012, 75: 68-72.CrossRefPubMed
78.
Baumgartner C, Osl M, Netzer M, Baumgartner D: Bioinformatic-driven search for metabolic biomarkers in disease. J Clin Bioinforma. 2011, 1: 2-10.1186/2043-9113-1-2.PubMedCentralCrossRefPubMed
79.
80.
Wang XD, Peer D, Petersen B: Molecular and cellular therapies: new challenges and opportunities. Mol Cell Therapies. 2013, 1: 1-10.1186/2052-8426-1-1.CrossRef
81.
82.
Abraham E, Marincola FM, Chen ZN, Wang XD: Clinical and translational medicine: integrative and practical science. Clin Transl Med. 2012, 1: 1-10.1186/2001-1326-1-1.PubMedCentralCrossRefPubMed
Metadata
Title
The therapeutic target of estrogen receptor-alpha36 in estrogen-dependent tumors
Authors
Yu Gu
Tianxiang Chen
Elena López
Weizhu Wu
Xiangdong Wang
Jiang Cao
Lisong Teng
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2014
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-12-16

Other articles of this Issue 1/2014

Journal of Translational Medicine 1/2014 Go to the issue

Research

Potential therapeutic targets for hypoxia-induced pulmonary artery hypertension

Research

An innovative system for 3D clinical photography in the resource-limited settings

Erratum

Erratum to: Clinical use of Dieletrophoresis separation for live Adipose derived stem cells

Research

miR-10b is overexpressed in hepatocellular carcinoma and promotes cell proliferation, migration and invasion through RhoC, uPAR and MMPs

Methodology

Empirical study using network of semantically related associations in bridging the knowledge gap

Research

Uncovering the cathepsin system in heart failure patients submitted to Left Ventricular Assist Device (LVAD) implantation
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits